Credit: IMBA/Tibor Kulcsar

UBC scientist discovers trial drug that can significantly block early stages of COVID-19 in engineered human tissues

Posted on

An international team led by UBC researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings hold promise as a treatment capable of stopping early infection of the novel coronavirus.

“We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” says Penninger, professor in UBC’s faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC….

https://news.ubc.ca/2020/04/02/ubc-led-study-finds-trial-drug-can-significantly-block-early-stages-of-covid-19-in-engineered-human-tissues/

Read More Impact Stories

Posted on
This article is only available in French. Lésion de la moelle épinière: stimuler la plasticité des neurones pour améliorer la [...]
Posted on
A comprehensive study by scientists at UdeM maps the evolutionary dynamics and risks of viral emergence of diseases that could [...]
Posted on
This article is available only in French. Infections respiratoires: mieux trier les patients pour soulager la pression sur les urgences [...]